The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | CheckMate 9LA: TMB and immune checkpoint inhibitor efficacy
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, shares an update on the CheckMate 9LA trial (NCT03215706) comparing nivolumab and ipilimumab combined with chemotherapy to chemotherapy alone in patients with first-line non-small cell lung cancer (NSCLC). Analysis of the association between blood and tissue tumor mutational burden (TMB) and efficacy found that clinical benefit was reported in both TMB-high and TMB-low subgroups, however, higher TMB seemed to be associated with improved progression-free survival and overall response rate in the nivolumab plus ipilimumab plus chemotherapy arm compared to the chemotherapy alone arm. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
